In 2024, Darnytsia Registered 10 Medicines Abroad and Entered Six New Markets

Darnytsia Pharmaceutical Company registered 10 medicines outside Ukraine in 2024 and expanded its presence to the markets of six new countries.

These new markets include EU countries, Bosnia and Herzegovina, Israel, New Zealand, and Malaysia.

Darnytsia introduced medicines in these countries designed for:

•    Comprehensive treatment of acute and chronic heart failure, acute and chronic kidney failure, nephrotic syndrome, liver diseases, and arterial hypertension;
•    Treatment and prevention of candidiasis infections;
•    Treatment and prevention of acute inflammatory diseases of the oral cavity and throat;
•    Systemic treatment and prevention of infectious diseases.

Most of the countries where Darnytsia has entered feature multi-level and strict regulatory frameworks, with high requirements for medicinal products and GMP standards. Darnytsia’s medicines meet the highest global standards for quality, efficacy, and safety.

“In 2024, Darnytsia unlocked new opportunities. For us, each new country is not just geography, but new health stories. We understand the global challenges in healthcare and provide medicines tailored to the needs of people, regardless of their location. I believe that Darnytsia’s medicines will strengthen global trust in Ukrainian pharmaceuticals,” said Anna Pavliuk-Havrylova, Head of the Department of International Registration and Market Expansion at Darnytsia Pharmaceutical Company.